JP Morgan Maintains Neutral on Molecular Partners, Lowers Price Target to $4

Benzinga · 09/03/2025 15:18
JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lowers the price target from $4.5 to $4.